Table II.
Feature | Total n=50 | miR-153-3p expression
|
P-value | |
---|---|---|---|---|
High | Low | |||
Sex | 0.4741 | |||
Male | 21 | 8 | 13 | |
Female | 29 | 14 | 15 | |
Age at presentation (years) | 0.1212 | |||
≤5 | 31 | 11 | 20 | |
>5 | 19 | 11 | 8 | |
Tumor enucleation location | 0.1443 | |||
Right | 24 | 8 | 16 | |
Left | 26 | 14 | 12 | |
Largest tumor base (mm) | 0.0199a | |||
≤15 | 32 | 18 | 14 | |
>15 | 18 | 4 | 14 | |
T classification | 0.1830 | |||
T1-2 | 28 | 10 | 18 | |
T3-4 | 22 | 12 | 10 | |
Clinical stage | 0.2008 | |||
I-II | 20 | 11 | 9 | |
III-IV | 30 | 11 | 19 | |
Differentiation | 0.0025b | |||
Well and moderate | 16 | 12 | 4 | |
Poor | 34 | 10 | 24 |
P<0.05;
P<0.01. The Chi-squared test was used for association analysis between clinicopathological features of patients with retinoblastoma and miR-153-3p expression profiles.